Amrize CEO Buys the Dip Ahead of Q3 Results

Amrize AG reports third-quarter results today, and the most striking pre-earnings signal came not from options desks or short sellers but from the company's own chairman and chief executive.

Jan Philipp Jenisch spent roughly CHF 1.27 million buying stock in early September, accumulating 30,000 shares across several tranches at prices between CHF 42.37 and CHF 42.53. None of the purchases were made under a pre-arranged 10b5-1 trading plan, making them discretionary bets. Several other executives followed in the same week: the Chief Legal Officer, the Chief Marketing and Corporate Affairs Officer, and the Chief Strategy and M&A Officer each added shares at similar prices around CHF 44 to CHF 47. At today's close of CHF 33.09, every one of those purchases is underwater by more than 20%, which frames the earnings release as a test of whether management's conviction was premature or prescient.

The short-selling community has no strong view in either direction. Short interest is modest at around 1.5% of the free float, and borrow availability is extremely loose, at roughly 1,725% of the shares already lent out, well above the 52-week trough of 378%. Borrowing costs are negligible at 0.57%. The ORTEX short score has drifted lower all week, from 32.5 on October 20 to 30.7 on October 27, a move that reflects easing, not building, short-side pressure. This is not a stock where bears are pressing ahead of the print.

Ownership adds one further wrinkle. Thomas Schmidheiny filed a Schedule 13D in June 2025, an activist-designation filing, declaring a 6.67% stake. That flag remains on the register, making him the most prominent holder after the passive giants. Vanguard Capital Management holds 5.32% on a separate 13G filed in April 2026, while BlackRock disclosed it trimmed its position from 6.9% to 3.6% in January 2026. As always with 13D/G filings, stakes are as last disclosed around the 5% threshold and positions may have changed since.

On valuation, the stock trades at roughly 13.8 times earnings and 8.1 times EV/EBITDA. The PE multiple has risen about 0.7 points over the past month as the shares recovered 5.4%, outpacing the median weekly gain of 1.0% among its closest peers. Holcim rose 4.8% over the same week, and Vulcan Materials added a modest 0.2%, placing Amrize's 3.2% weekly gain broadly in line with sector sentiment. The dividend score ranks in the 94th percentile, a reflection of the special one-time dividend approved in April, though the earnings-yield and forward EPS momentum readings are more middling.

The results will say whether the construction materials cycle has stabilised enough to justify the recovery in the share price, or whether management's September share purchases were simply too early.